Abbott Laboratories $ABT Shares Sold by PDS Planning Inc

PDS Planning Inc trimmed its position in Abbott Laboratories (NYSE:ABT) by 8.5% during the second quarter, Holdings Channel.com reports. The firm owned 109,606 shares of the healthcare product maker’s stock after selling 10,129 shares during the period. Abbott Laboratories accounts for about 0.6% of PDS Planning Inc’s holdings, making the stock its 24th largest holding. PDS Planning Inc’s holdings in Abbott Laboratories were worth $9,946,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Nia Impact Advisors LLC lifted its stake in shares of Abbott Laboratories by 2.2% during the second quarter. Nia Impact Advisors LLC now owns 3,706 shares of the healthcare product maker’s stock valued at $504,000 after buying an additional 79 shares during the period. Riggs Asset Managment Co. Inc. grew its stake in Abbott Laboratories by 9.3% in the 2nd quarter. Riggs Asset Managment Co. Inc. now owns 1,031 shares of the healthcare product maker’s stock worth $140,000 after acquiring an additional 88 shares during the period. Eley Financial Management Inc raised its holdings in Abbott Laboratories by 0.9% in the 4th quarter. Eley Financial Management Inc now owns 10,817 shares of the healthcare product maker’s stock valued at $1,355,000 after acquiring an additional 92 shares during the last quarter. Copley Financial Group Inc. lifted its stake in shares of Abbott Laboratories by 2.1% during the 4th quarter. Copley Financial Group Inc. now owns 4,435 shares of the healthcare product maker’s stock worth $556,000 after purchasing an additional 93 shares during the period. Finally, Kelleher Financial Advisors boosted its holdings in shares of Abbott Laboratories by 2.9% during the third quarter. Kelleher Financial Advisors now owns 3,301 shares of the healthcare product maker’s stock worth $442,000 after purchasing an additional 93 shares during the last quarter. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: The FDA authorized Abbott’s Libre Duo 10 Day, the first continuous monitor designed to track both glucose and ketone levels. The device could strengthen Abbott’s FreeStyle Libre ecosystem, help identify rising ketones before diabetic ketoacidosis emergencies, and support compatibility with automated insulin-delivery systems. Reuters article
• Positive Sentiment: TD Cowen raised its price target for ABT to $135 from $115 and maintained a “buy” rating. The upgrade signals confidence in Abbott’s growth prospects, particularly in continuous glucose monitoring and medical devices. Benzinga article
• Positive Sentiment: Medtronic’s MiniMed Flex insulin pump has begun shipping with an Abbott-made glucose sensor, expanding the potential distribution and application of Abbott’s sensor technology in automated insulin delivery. MedTech Dive article
• Neutral Sentiment: Recent comparisons portray Abbott as a relatively attractive healthcare and continuous glucose monitoring investment, citing valuation, liquidity and price-target upside. These assessments may support sentiment but do not represent new company operating results. Yahoo Finance article
• Negative Sentiment: Abbott agreed to pay $670 million to settle claims that its specialized premature-infant formulas contributed to necrotizing enterocolitis. The settlement removes some litigation uncertainty but highlights continuing legal and financial risks. Insider Monkey article
• Negative Sentiment: Diagnostics growth remains uneven: strong routine testing and 13% cancer-diagnostics growth are being partly offset by weaker respiratory testing demand. This could temper near-term revenue momentum. Yahoo Finance article

Abbott Laboratories Price Performance

ABT stock opened at $116.12 on Wednesday. The stock has a 50-day moving average price of $101.15 and a two-hundred day moving average price of $100.09. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $137.49. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57. The company has a market cap of $200.94 billion, a PE ratio of 37.58, a price-to-earnings-growth ratio of 2.26 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. The company had revenue of $12.59 billion for the quarter, compared to the consensus estimate of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The company’s quarterly revenue was up 13.0% compared to the same quarter last year. During the same period last year, the business posted $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, research analysts predict that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, August 17th. Investors of record on Wednesday, July 15th were issued a $0.63 dividend. The ex-dividend date was Wednesday, July 15th. This represents a $2.52 annualized dividend and a yield of 2.2%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 81.55%.

Wall Street Analyst Weigh In

Several equities analysts recently commented on ABT shares. JPMorgan Chase & Co. upped their target price on Abbott Laboratories from $110.00 to $120.00 and gave the company an “overweight” rating in a research note on Friday, July 17th. Weiss Ratings raised Abbott Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, August 6th. Citigroup upped their price objective on shares of Abbott Laboratories from $108.00 to $112.00 and gave the company a “buy” rating in a research note on Friday, July 17th. Wells Fargo & Company increased their price objective on shares of Abbott Laboratories from $109.00 to $112.00 and gave the stock an “overweight” rating in a report on Friday, July 17th. Finally, Robert W. Baird started coverage on shares of Abbott Laboratories in a report on Wednesday, July 1st. They issued an “outperform” rating and a $121.00 target price for the company. Three investment analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Abbott Laboratories has a consensus rating of “Moderate Buy” and a consensus target price of $119.50.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.